Candriam Luxembourg S.C.A. acquired a new position in Shire PLC (NASDAQ:SHPG) during the second quarter, Holdings Channel reports. The institutional investor acquired 7,113 shares of the biopharmaceutical company’s stock, valued at approximately $1,309,000.
Several other hedge funds have also recently bought and sold shares of SHPG. Boston Advisors LLC raised its stake in shares of Shire PLC by 3,008.9% in the second quarter. Boston Advisors LLC now owns 87,206 shares of the biopharmaceutical company’s stock worth $16,053,000 after buying an additional 84,401 shares during the period. Cullen Frost Bankers Inc. bought a new stake in shares of Shire PLC during the second quarter worth about $17,387,000. Conning Inc. bought a new stake in shares of Shire PLC during the second quarter worth about $365,000. Canandaigua National Bank & Trust Co. bought a new stake in shares of Shire PLC during the second quarter worth about $239,000. Finally, Deltec Asset Management LLC raised its stake in shares of Shire PLC by 266.4% in the second quarter. Deltec Asset Management LLC now owns 32,975 shares of the biopharmaceutical company’s stock worth $6,070,000 after buying an additional 23,975 shares during the period. 24.26% of the stock is currently owned by institutional investors.
Shire PLC (NASDAQ:SHPG) traded down 0.11% during trading on Wednesday, reaching $194.37. The company’s stock had a trading volume of 1,130,759 shares. Shire PLC has a 52-week low of $147.60 and a 52-week high of $231.32. The firm’s 50-day moving average is $195.77 and its 200-day moving average is $186.79. The stock has a market cap of $57.89 billion, a P/E ratio of 40.39 and a beta of 1.16.
Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.03 by $0.35. The firm earned $2.43 million during the quarter, compared to the consensus estimate of $2.28 billion. Shire PLC had a net margin of 13.19% and a return on equity of 17.70%. The business’s revenue for the quarter was up 55.9% compared to the same quarter last year. During the same period last year, the business posted $2.63 earnings per share. Equities research analysts forecast that Shire PLC will post $12.92 EPS for the current year.
The business also recently disclosed a dividend, which will be paid on Friday, October 7th. Shareholders of record on Friday, September 9th will be given a dividend of $0.139 per share. The ex-dividend date is Wednesday, September 7th. Shire PLC’s dividend payout ratio (DPR) is presently 15.63%.
SHPG has been the topic of a number of recent analyst reports. HSBC lowered Shire PLC from a “buy” rating to a “hold” rating in a research report on Monday, September 26th. Shore Capital reiterated a “buy” rating on shares of Shire PLC in a report on Tuesday, August 30th. Citigroup Inc. reiterated a “buy” rating on shares of Shire PLC in a report on Tuesday, September 27th. Zacks Investment Research upgraded Shire PLC from a “hold” rating to a “buy” rating and set a $208.00 price target on the stock in a report on Tuesday, July 5th. Finally, Jefferies Group reiterated a “buy” rating and set a $262.00 price target on shares of Shire PLC in a report on Tuesday, September 20th. Five investment analysts have rated the stock with a hold rating and twenty-two have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $232.75.
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.